Nektar Therapeutics (NKTR) Research & Development (2010 - 2026)

Nektar Therapeutics' Research & Development history runs 17 years deep, the most recent figure standing at $35.7 million for Q1 2026.

• In Q1 2026, Research & Development rose 17.06% year-over-year to $35.7 million; the TTM figure through Mar 2026 stood at $122.5 million (down 1.17% YoY), while the FY2025 annual figure was $117.3 million, down 2.96% from the prior year.
• Research & Development was $35.7 million for Q1 2026 at Nektar Therapeutics, up from $29.7 million in the prior quarter.
• In the past five years, Research & Development ranged from a high of $107.3 million in Q1 2022 to a low of $24.1 million in Q3 2023.
• Historically, Research & Development has averaged $35.7 million across 5 years, with a median of $29.9 million in 2023.
• The sharpest annual moves came in 2023 and 2024: Research & Development tumbled 71.59% in 2023, then jumped 45.54% in 2024.
• A 5-year view of Research & Development shows it stood at $34.7 million in 2022, then fell by 13.81% to $29.9 million in 2023, then dropped by 4.0% to $28.7 million in 2024, then rose by 3.36% to $29.7 million in 2025, then climbed by 20.09% to $35.7 million in 2026.
• The last three Research & Development figures came in at $35.7 million (Q1 2026), $29.7 million (Q4 2025), and $27.3 million (Q3 2025), per Business Quant data.